Zylox-Tonbridge Medical Technology Co (FRA:818) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:818 Zylox-Tonbridge Medical Technology Co Ltd FRA:818
76 GF Score
Price €2.08
GF Value €3.72
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zylox-Tonbridge Medical Technology Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Zylox-Tonbridge Medical Technology Co Quality Rank Related Terms

FRA:818
76GF Score
Zylox-Tonbridge Medical Technology Co Ltd FRA:818
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zylox-Tonbridge Medical Technology Co (FRA:818) Overvalued in 2026?

Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued. The current stock price of €2.08 is trading 44.1% below its estimated GF Value™ of €3.72. GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.

Key valuation signals for FRA:818:

  • Quality Rank:
  • GF Value™: €3.72 vs. price of €2.08 (44.1% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the FRA:818 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zylox-Tonbridge Medical Technology Co Business Description

Other Exchanges 02190:Hong Kong
Address 270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
76GF Score

Get the complete analysis for FRA:818

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.08
Price
€3.72
GF Value